Found an issue? Give us feedback

Link to

shareShare

uploadDeposit

codeEmbed

downloadDownload

Select content type to embed

All Research products

arrow_drop_down

<script type="text/javascript">
<!--
document.write('<div id="oa_widget"></div>');
document.write('<script type="text/javascript" src="https://www.openaire.eu/index.php?option=com_openaire&view=widget&format=raw&projectId=inca________::16ee58cfb9cd0022efaa267cdda70e29&type=result"></script>');
-->
</script>

COPY SCRIPT

For further information contact us at helpdesk@openaire.eu

A randomized, comparative, multicenter, open-label phase II study to evaluate the efficacy and safety of pazopanib/paclitaxel versus paclitaxel alone in patients with anaplastic thyroid cancer metastatic and/or relapsing after initial standard treatment.

assignment_turned_inproject

Funder: Institut National du CancerProject code: INCa-DGOS-3758 Call for proposal: PHRC11

Funded under: PHRC

A randomized, comparative, multicenter, open-label phase II study to evaluate the efficacy and safety of pazopanib/paclitaxel versus paclitaxel alone in patients with anaplastic thyroid cancer metastatic and/or relapsing after initial standard treatment.

- Summary
- DMPs

Partners

CHU Marseille - Hôpital la Timone , Institut Jean Godinot , Institut de Cancérologie de l'Ouest , Centre Léon Bérard , Groupe Hospitalier Pitié Salpétrière , Centre François Baclesse , HCL , Hôpital Saint-Louis , Centre Hospitalier Régional et Universitaire de Lille , Institut Gustave Roussy

Data Management Plans

Start a new DMP in Argos

Found an issue? Give us feedback

Select content type to embed

All Research products

arrow_drop_down

<script type="text/javascript">
<!--
document.write('<div id="oa_widget"></div>');
document.write('<script type="text/javascript" src="https://www.openaire.eu/index.php?option=com_openaire&view=widget&format=raw&projectId=inca________::16ee58cfb9cd0022efaa267cdda70e29&type=result"></script>');
-->
</script>

COPY SCRIPT

For further information contact us at helpdesk@openaire.eu

A randomized, comparative, multicenter, open-label phase II study to evaluate the efficacy and safety of pazopanib/paclitaxel versus paclitaxel alone in patients with anaplastic thyroid cancer metastatic and/or relapsing after initial standard treatment.

A randomized, comparative, multicenter, open-label phase II study to evaluate the efficacy and safety of pazopanib/paclitaxel versus paclitaxel alone in patients with anaplastic thyroid cancer metastatic and/or relapsing after initial standard treatment.

Loading